Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review
International Journal of Molecular Sciences · 19.08.2024 · 25 (16) · 9010
DOI: 10.3390/ijms25169010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2024. Verfasst von Rong-Rong He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. Hauptthemen laut MEDLINE: Sepsis, Biomarkers. Die Arbeit wurde bisher 171-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis is now defined as a life-threatening syndrome of organ dysfunction triggered by a dysregulated host response to infection, posing significant challenges in critical care. The main objective of this review is to evaluate the potential of emerging biomarkers for early diagnosis and accurate prognosis in sepsis management, which are pivotal for enhancing patient outcomes. Despite advances in supportive care, traditional biomarkers like C-reactive protein and procalcitonin have limitations, and recent studies have identified novel biomarkers with increased sensitivity and specificity, including circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2. These emerging biomarkers hold promising potential for the early detection and prognostication of sepsis. They play a crucial role not only in diagnosis but also in guiding antibiotic therapy and evaluating treatment effectiveness. The introduction of point-of-care testing technologies has brought about a paradigm shift in biomarker application, enabling swift and real-time patient evaluation. Despite these advancements, challenges persist, notably concerning biomarker variability and the lack of standardized thresholds. This review summarizes the latest advancements in sepsis biomarker research, spotlighting the progress and clinical implications. It emphasizes the significance of multi-biomarker strategies and the feasibility of personalized medicine in sepsis management. Further verification of biomarkers on a large scale and their integration into clinical practice are advocated to maximize their efficacy in future sepsis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
ORCID-Profile: Mei-Ling Dong, Chen Cheng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, R. R., Yue, G. L., Dong, M. L., Wang, J. Q., & Cheng, C. (2024). Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review. International Journal of Molecular Sciences, 25(16), 9010. https://doi.org/10.3390/ijms25169010
Vancouver
He RR, Yue GL, Dong ML, Wang JQ, Cheng C. Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review. International Journal of Molecular Sciences. 2024;25(16):9010. doi:10.3390/ijms25169010
BibTeX
@article{He2024,
author = {He, Rong-Rong and Yue, Guo-Li and Dong, Mei-Ling and Wang, Jia-Qi and Cheng, Chen},
title = {Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {9010},
doi = {10.3390/ijms25169010}
}
EUVIMED